Both HER-2 and EGFR are expressed in breast cancer and are implicated in its
development and progression. The discovery of the association between HER-2 gene …

HER2 positive breast cancer is characterized by the low survival rate in the metastatic
patients. Development of resistance and disease-relapse are the major problems associated …

From the early experience with tamoxifen to the current use of Herceptin®, targeted therapy
has been proven to be an important part of breast cancer (BC) treatment. In the last decade …

The body of evidence investigating human epidermal growth factor receptor-2 (HER2)
directed therapy in patients with breast cancer (BC) has been growing within the last …

Protein tyrosine kinases are tightly regulated enzymes that play an important role in the
control of most fundamental cellular processes, including cell proliferation, differentiation …

Epidermal Growth Factor Receptor (EGFR), a type-I transmembrane protein with intrinsic
tyrosine kinase activity, is activated by peptide growth factors such as EGF, epigen …

Novel cancer therapies have focused on specific molecular markers present in malignant
tumors. The rationale of targeted therapy relies on the knowledge of molecular mechanisms …

Recent trials of drug therapy targeting the erbB receptor HER2 have met with success in
breast cancer. The epidermal growth factor receptor or EGFR is a closely related receptor …

Combining different anti-HER2-targeted agents represents a promising therapeutic strategy,
now reaching clinical practice. There are major clinical challenges yet to be resolved, rising …

Breast cancer (BC) is the most common malignancy in women and one of the leading
causes of cancer mortality, despite significant treatment advancements over the last …